RSS Feed For (NASDAQ:BIIB)

BIOGEN IDEC (NASDAQ:BIIB)

46.38 +0.53 (1.16%)
BIOGEN IDEC (NASDAQ:BIIB) Delayed :
Previous Close $45.85    52 Week High $55.34 
Open $45.60    52 Week Low $5.93 
Day High $46.52    P/E 15.56 
Day Low $45.56    EPS $2.98 
Volume 2,829,055       
More BIIB Info: Chart SEC Filings Profile Historical Options

Biogen Idec Summary

Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid ...more

Executives

James C. Mullen - CEO

Links

http://www.biogenidec.com

What is this?Friends, Peers and Foes

Ticker # Stories Ticker # Stories
ELN 19 FACT 14
AMGN 10 GENZ 10
GILD 9 AMLN 9
PFE 7 JNJ 6
WYE 6 GOOG 5
LIFE 5 CELG 5
View All Friends, Peers and Foes

StreetInsider Reports on BIIB by Category

View All Comments Comments on recent BIIB articles

kevin.lafeber@acs-inc.com
on Sep 21, 2009
at 07:20 PM
Dell and Perot Interesting
Article: Notable Mergers and Acquisitions of the Day 9/21: DELL/PER, HK, IMA, BIIB/FACT

on Jan 29, 2009
at 07:08 PM
Clueless! They probably have large investments in TEVA Pharmaceuticals
Article: Brean Murray Initiates Coverage on Biogen Idec (BIIB) with a Sell

on Jan 29, 2009
at 06:16 AM
What a bunch of Idiots Who would listen to a sub par investment bank like Brean Murray Carret? Disregard the sell - look at the pipeline! I'm expecting good earnings for Q4
Article: Brean Murray Initiates Coverage on Biogen Idec (BIIB) with a Sell
mick432
on Jan 28, 2009
at 09:10 PM
re: 5 consecutive knockouts What are these guys thinking? BIIB will continue to surprise us with top notch earnings and a terrific pipeline.
Article: Brean Murray Initiates Coverage on Biogen Idec (BIIB) with a Sell
btour
on Oct 28, 2008
at 09:45 AM
bout time Finally someone realises the value. This stock is cheaper than in 95 although earnings have grown, company has bought in stock, and it is a good takeover prospect. Even in a deep recession they will do well. Suffering from the Dow blues, margin calls, and hedge fund unwinding, this stock will bounce high.
Article: Cowen & Co Upgrades Biogen Idec (BIIB) to Outperform, Calls Best Value In Biotech
View All Comments

Comments on BIIB


No comments are currently available.